66results about How to "Constant release rate" patented technology

Compositions containing a mixture of microcapsules and a bulk polymer, where the microcapsules have an oil field chemical contained within the microcapsules are described. The microcapsules can be present in a variety of configurations. The microcapsules contain a core or a micro-matrix containing the oil field chemicals. The core or micro-matrix can be surrounded by one or more polymeric shells, where each shell contains at least one polymer that affects the release of the oil field chemical from the composition. The compositions provide for the sustained release of an oil field chemical into fluid in an oil field reservoir over long periods of time. Methods of making the compositions and articles containing the compositions are described. Methods of tracing the movement of fluid in a hydrocarbon reservoir using the compositions, and methods of providing for the sustained release of oil field chemicals are also described.

A dispenser of actives having a linear release rate may be achieved by providing a volatile containing gel system wherein the gel system is proportioned in specified dimensional ratios, so that the sum of the rate of volatile release from directly exposed areas of the surface of the gel system and the rate of volatile release from areas of the surface of the gel system which are not in direct exposure to the atmosphere remains essentially constant through out the life of the dispensing device.

An open gel system for delivery of an active volatile possesses dimensions in the x, y, and z directions such as to release actives at an essentially constant rate from initiation of volatilization until completion of volatilization.

The invention provides an oral ciclosporin A sustained-release agent. The sustained-release agent comprises the following components in part by mass: 1 part of ciclosporin A, 2.5 to 7.5 parts of polyvidone-K30, 0.15 to 4.82 parts of hydroxypropyl methyl cellulose 4000cPa.s, 0.1 to 3.94 parts of microcrystalline cellulose, 0 to 2.57 parts of hydroxypropyl methyl cellulose 15000cPa.s and 0.1 to 1.0part of phospholipid. By combining a solid dispersing technology and a sustained-release hydrophilic gel matrix technology and based on the 'double release' principle of fast release first and slow release second, the method prepares the insoluble medicament of ciclosporin A sustained-release agent; and the method has the obvious advantages that the solubility of ciclosporin A is improved, and the oral agent can quickly play the effect first and then smoothly and slowly release drug. The ciclosporin A sustained-release tablets reduce the lowered blood concentration peak-valley phenomenon and lower the drug-taking frequency. The invention also discloses a method for preparing the oral ciclosporin A sustained-release agent.

A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more porous partitions, where the pores of the partitions are sufficiently small to retain the insoluble powder particles within the reservoir yet large enough to allow diffusion of the active agent once the device is hydrated. A therapeutic dose of the drug is released from the device at a constant rate over a period of approximately 2-6 months.

The invention discloses water-retention and fertilizer-retention air ventilation nutritional soil. The water-retention and fertilizer-retention air ventilation nutritional soil is prepared from the following raw materials in parts by weight: 20 to 40 parts of garden soil, 15 to 25 parts of leaf mold, 5 to 18 parts of rice chaff ash, 2 to 9 parts of ammonium chloride, 1 to 6 parts of ground phosphate rock, 2 to 8 parts of potassium nitrate, 4 to 10 parts of fish bone meal, 10 to 20 parts of germinated brown rice, 2 to 8 parts of castor meal, 3 to 6 parts of oil residues, 4 to 10 parts of earthworm excretion, 0.01 to 0.06 part of diaminoferric xanthohumate, 1 to 2 parts of sepiolite powder, 2 to 6 parts of grass carbon, 2 to 4 parts of diatomite, 0.5 to 1.5 parts of shell powder, 10 to 20 parts of alfalfa, and 5 to 15 parts of tobacco stem and clay compound. The water-retention and fertilizer-retention air ventilation nutritional soil has the advantages that the degrading rate and nutrient releasing rate can be regulated, the utilization rate of fertilizer is high, nitrogen, phosphor and potassium necessary to the growth of plants can be provided, the releasing rate meets the growth rule of the plants, the slow-release effect is obvious, and the heat stability is good.

Injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

The invention discloses a sustained-release microsphere to achieve the aims of contraception and long-term treatment of endometriosis uterine, which comprises the following components: (1) nomegestrol acetate or analogs thereof, and (2) a biodegradable polymer, wherein the weight ratio of an ester-terminated polymer to a carboxyl-terminated polymer is between 1:0.01-1:1; the ester-terminated polymer is selected from polylactide-glycolide, polylactide, poly-beta-hydroxybutyrate, poly ortho ester, polycaprolactone, poly-phosphate, polyanhydride, or poly-cyanoacrylate; the carboxyl-terminated polymer is selected from polyglycolic acid and polylactic acid-glycolic acid; and the weight of the nomegestrol acetate or the analogs thereof accounts for 5 to 80 percent of the total weight of the microsphere. The invention also discloses a preparation method and application of the sustained-release microsphere.

The invention relates to a choline fenofibrate film-controlled enteric slow-release pellet capsule. A slow-release film of the choline fenofibrate film-controlled enteric slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the choline fenofibrate film-controlled enteric slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains a pharmaceutically acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of urdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 20 to 38%. The choline fenofibrate film-controlled enteric slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the choline fenofibrate film-controlled enteric slow-release pellet expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the choline fenofibrate film-controlled enteric slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a venlafaxine hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the venlafaxine hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the venlafaxine hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 21 to 39%. The venlafaxine hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the venlafaxine hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the venlafaxine hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The present invention relates to an enteric, sustained-release tablet comprising paroxetine or a hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active substance, more particularly to a tablet prepared by coating a sustained-release tablet core containing paroxetine with an enteric polymer, wherein the interaction between the tablet core and the enteric coating layer is minimized to enable constant drug release without regard to the residence time of the tablet in the stomach.

The invention relates to a controlled release transdermal patch for preventing and treating cardiovascular and cerebrovascular system diseases, which consists of a protectively layer, a medicine release layer, a medicine storage layer and a back lining layer through being sequentially overlapped, wherein the protectively layer is siliconized anti-sticking paper or a polyethylene film or a siliconized polyester film, the back lining layer is an aluminum foil, an aluminum foil and polyethylene composite film or a polyester composite film, the medicine releasing layer is prepared from 3 to 8 percent of cyclovimbuxine D, 60 to 70 percent of pressure sensitive adhesive substrates, 5 to 10 percent of composite transdermal penetrating agents, 20 to 30 percent of plasticizing agents and 1 to 3 percent of cross-linking agents, the medicine storage layer consists of 8 to 15 percent of the cyclovimbuxine D, 50 to 60 percent of the pressure sensitive adhesive substrates, 1 to 5 percent of composite transdermal penetrating agents, 20 to 30 percent of plasticizing agents and 1 to 3 percent of cross-linking agents. The patch of the invention is prepared by an organic solvent dispersing method, the preparation process is simple, the prepared patch has the exact curative effect, stable quality, high safety and convenient use, and is applicable to the long-time prevention and treatment of the cardiovascular and cerebrovascular diseases.

The invention relates to a novel matrix sustained-release tablet containing loxoprofen sodium, in particular to a locoprofen sodium matrix sustained-release tablet with a regulation layer, which is capable of stably releasing for 8 hours, good in releasing effect, simple in process and low in cost.

The invention belongs to the field of medicinal preparation and specifically provides a posaconazole double-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet comprises a tablet core and a semipermeable controlled release film. The tablet core comprises a drug containing layer and a boosting layer. The drug containing layer is located inside the controlled release film which is provided with a drug releasing hole. The boosting layer is located inside the controlled release film at a place far away from the drug releasing hole. One end of the water-permeable controlled release film is provided with one or more drug releasing holes. The release curve of the preparation drug shows a zero-order release pattern, and thus the problem of drug resistance caused by long-term use of posaconazole dosage forms on the market is solved. Besides, the problems that the preparation technology is complex, the preparation cost is high, and the drug is unsuitable for industrialized mass production due to the adoption of a hot-melt extrusion technology are solved. Simultaneously, the in vivo-in vitro correlation of the drug is better ensured and the clinical monitoring of plasma concentration is better facilitated.

Provided is a sustained releaser of a sex pheromone having a high release rate, especially preferably of a sex pheromone of an aliphatic acetate compound having 10 to 16 carbon atoms, wherein the release of the sex pheromone is controlled so that it can be released at a constant rate over a control period of a pest insect. More specifically, provided is a sustained pheromone releaser comprising a polymer container and having, enclosed therein, a mixture having a melting point of 15 to 35° C. and being obtained by mixing a sex pheromone substance and a compound having a melting point of 10 to 40° C.

The invention relates to a cefaclor film-controlled slow-release pellet capsule. A slow-release film of the cefaclor film-controlled slow-release pellet utilizes a mixture of aqueous dispersion Eurdragit RL 30D and Eurdragit RS 30D as a film-formation material, wherein a weight ratio of Eurdragit RL 30D to Eurdragit RS 30D in the mixture is 4: 1. A pellet core of the cefaclor film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose, and the pellet core comprises 5 to 20wt% of the sodium carboxymethyl starch. The slow-release film comprises the mixture of Eurdragit RL 30D and Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to Eurdragit RS 30D to triethyl citrate to talcum powder is 24: 6: 2: 4 and a film weight increasing ratio is in a range of 23 to 40%. The cefaclor film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the cefaclor film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the cefaclor film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention relates to a metoprolol fumarate film-controlled slow-release pellet capsule. A slow-release film of the metoprolol fumarate film-controlled slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the metoprolol fumarate film-controlled slow-release pellet contains croscarmellose sodium having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 5 to 20wt% of croscarmellose sodium. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 18 to 33%. The metoprolol fumarate film-controlled slow-release pellet comprises the pellet core containing croscarmellose sodium having high water expansibility and thus after absorbing water, the metoprolol fumarate film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the metoprolol fumarate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention discloses a method for preparing an indapamide sustained-release preparation. The preparation method includes the following steps: premixing microcrystalline cellulose, lactose, indapamide and starch, making acrylic resin, triethyl citrate and talcum powder into a suspension using water, spraying most suspension into the premixed material in an atomizing manner at a high mixing speed and a high cut-off velocity, reducing the mixing speed and adding the remaining suspension, and stirring continuously at a low speed to prepare sustained-release pellets; in combination with pharmaceutically acceptable excipients, carrying out tablet coating or filling hollow capsules to prepare the sustained-release preparation. The method provided by the invention not only solves the defects that the drug applying rate is low, active substances are liable to crystal transformation, and the stability is low, but also solves the problems that the production safety is low and environment pollution is caused due to the use of a large amount of organic solvents when high-viscosity sustained-release framework materials are prepared into granules. The production process of the invention is simple, safe and environment-friendly, and avoids loss of active ingredient substances; the prepared drug can keep a constant release speed after being taken, and can continuously and stably lower the blood pressure.